Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Zydus announces patient enrollment in EVIDENCES VII Phase 2 clinical trial of Saroglitazar Magnesium in NAFLD with PCOS

Posted On: 2019-08-21 11:54:52

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has initiated a Phase 2 clinical trial for evaluating the effect of Saroglitazar Mg in the treatment of NonAlcoholic Fatty Liver Disease (NAFLD) in women with polycystic ovary syndrome (PCOS). The EVIDENCES VII trial is currently recruiting patients across several clinical sites in the United States of America and Mexico. [ClinicalTrials.gov Identifier: NCT03617263]

Research suggests that in women with polycystic ovary syndrome (PCOS), the risk for NonAlcoholic Fatty Liver Disease is increased. PCOS affects fertility and also significantly increases metabolic complications.

Speaking on the development, Mr. Pankaj R. Patel, Chairman, Zydus Group said, "We are happy with the progress of our investigational molecule, Saroglitazar Mg in the study for addressing several unmet healthcare needs including Non-Alcoholic SteatoHepatitis and NAFLD. Our research programme aims at bringing innovative therapies that make a difference to human lives in keeping with our mission to create healthier communities."

There is a high prevalence of PCOS in the general population affecting 1 in 10 women of childbearing age, causing infrequent or prolonged menstrual periods or excess male hormone (androgen) levels. Polycystic ovary syndrome (PCOS) is caused due to factors like obesity or insulin resistance, affecting liver function and leading to Non-Alcoholic Fatty Liver Disease (NAFLD). There are currently no treatments approved by the US. Food and Drug Administration (USFDA) for treatment of NAFLD or NASH.

The trial will evaluate the change in hepatic fat content from baseline following 24 weeks of treatment as measured by MRI-PDFF in patients treated with Saroglitazar Magnesium as compared to placebo as the primary endpoint. The secondary endpoints of the trial also include measurements of liver enzymes, insulin resistance, liver fibrosis, liver stiffness, BMI, waist circumference, MRIderived measures of total liver fat index, MRI-derived measures of total liver volume, lipid and lipoprotein levels, SHBG level, ovarian function, free androgen index and pharmacokinetic parameters.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.219.9 as compared to the previous close of Rs. 218.65. The total number of shares traded during the day was 43779 in over 808 trades.

The stock hit an intraday high of Rs. 220 and intraday low of 214.55. The net turnover during the day was Rs. 9555100.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

KSB Ltd Q4 PAT rises to Rs. 30.5 crore

IndusInd Bank Ltd approves appointment of Mr. Sumant Kathpalia as MD & CEO

IndiGo partners with HDFC Bank to launch its first credit card 'Ka-ching', powered by Mastercard

Vedanta Limited board approves 1st interim dividend of Rs. 3.9

Kalpataru Power Transmission Ltd board to consider dividend on Mar 4, 2020

S&P reaffirms long term rating of Samvardhana Motherson Automotive Systems Group B V

Mahindra Lifespace Developers Ltd acquires land in Pune

CARE updates on rating of KPI Global Infrastructure Limited

ADOR Fontech Ltd board approves interim dividend of Rs. 1.80

Brickworks Rating downgrades credit rating of Capital Trust Ltd

Government of India increases stake in IOB to 95.84% through preferential issue

UFO Moviez India Ltd board declares interim dividend of Rs. 15

Resonance Specialties Ltd board to consider interim dividend on Mar 4, 2020

Jamna Auto Industries Ltd Board to consider Second Interim Dividend

Mishra Dhatu Nigam Ltd Board to consider Dividend on Mar 3, 2020

Pidilite Industries announces acquisition of majority stake in Tenax India Stone Products Pvt. Ltd.

KRBL Ltd board declares interim dividend of Rs. 2.80

Lemon Tree Hotels announces its debut in Bhutan, with the launch of Lemon Tree Hotel, Thimphu

AudioCodes Selected by HFCL for Major Indian Government Telecom Network

Brickwork Ratings downgrades rating of Ganesh Housing Corporation Ltd

Newgen Software Technologies Ltd to set up unit at Noida SEZ

Canara Bank to sell 3.25% in Petronet MHB Ltd

Manappuram Finance Ltd board declares interim dividend of Rs. 0.55 for FY2020

Hexaware's Workforce Management team wins the 'Most Indigenous Practice in WFM' award at Global WFM awards

KSB Ltd board recommends dividend of Rs. 8 for CY2019

Jubilant FoodWorks Ltd board declares interim dividend of Rs. 6

Excel Industries Ltd Board to consider Interim Dividend on Mar 9, 2020

TCS Recognized as a Global Top Employer for Fifth Consecutive Year

Lincoln Pharmaceuticals Ltd board declares interim dividend of Rs. 1.50

Wipro Opens New Designit Studio in Dallas to Expand Reach of Design Innovation

Hero MotoCorp launches BSVI version of New Super Splendor

Relaxo Footwears Limited board declares interim dividend of Rs. 1.25

IndiaMART becomes first B2B marketplace in India to register 10 Cr users on the platform

Bank of Baroda to sell 4.90% stake in Petronet MHB Ltd

NLC India Ltd board approves interim dividend of Rs. 7.06

Seamec Ltd deploys SEAMEC III at Mumbai High Offshore

Finolex Industries Ltd board declares interim dividend of Rs. 10 for FY20

Acko Partners with HDB Financial Services to Offer Micro Insurance on HDB Aabhar Cards

Airtel Payments Bank rolls out Aadhaar enabled Payment System (AePS) across 250,000 Banking Points

Apollo Tyres executes investment agreement with Warburg Pincus arm

Som Distilleries & Breweries Ltd updates on credit ratings

GOCL Corporation Ltd updates on accident at Hyderabad factory

Faze Three Ltd board to consider interim dividend on Mar 3, 2020

Precision Camshafts Ltd board to consider interim dividend on Mar 5, 2020

Maithan Alloys Ltd board approves interim dividend of Rs. 6

Cupid Ltd Board to consider Second Interim Dividend on Mar 4, 2020

PNB Housing Finance Ltd board to consider fund raising on Mar 3, 2020

Meghmani Organics Ltd board to approve dividend on Mar 3, 2020

Glenmark Pharmaceuticals and Hikma enter into an Exclusive Licensing Agreement for commercializing Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in the US

Dr. Reddy's Laboratories announces the first generic launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets in the U.S. Market







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019